Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 Europe AstraZeneca, showed significant improvements in overall survival in people with BRCA-mutated (gBRCAm), HER2-negative, high-risk early-stage cancers. of breast, clinical trial of 2024. data suggest.
Jaime Grajales Bennjumea—Getty Images